The Effects of Wintergreen Essential Oil Inhalation on Alleviating Dyspnea Among Patients With Pneumonia
Key facts
- Who runs it
- Far Eastern Memorial Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 84 people, planned
- Started
- 19 Oct 2026
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional, 7 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Sunflower oil inhalation
- 1% Linalool inhalation
- Wintergreen essential oil inhalation
- Record updated
- 26 October 2026
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Primary diagnosis of pneumonia with dyspnea symptoms
- Admitted with ICD-10 diagnosis codes: Influenza and viral pneumonia (J10-J12), Bacterial pneumonia (J13-J15), Other infectious agents (J16-J17), or Unspecified organism pneumonia (J18.9)
- Aged 18 to 90 years
- Clear consciousness (Glasgow Coma Scale: 15) with normal mental and behavioral capacity
- Able to communicate verbally or non-verbally and comprehend Mandarin or Taiwanese
Who cannot take part
- Currently receiving non-invasive positive pressure ventilation (NIPPV, BiPAP), high-flow nasal cannula (HFNC), or oxygen masks (such as Simple mask, Non-rebreathing mask)
- Dementia (including Alzheimer's disease, Parkinson's disease, etc.)
- Acute psychiatric symptoms precluding communication
- Known allergy or hypersensitivity to salicylates, aspirin, or nonsteroidal anti-inflammatory drugs (NSAIDs)
- Anosmia or severe nasal diseases
- History of asthma
- History of very severe chronic obstructive pulmonary disease (COPD): GOLD stage 4 (FEV1 < 30% predicted)
- Pregnant or lactating women
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Pneumonia or dyspnea
This trial is currently available in Taiwan.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pneumonia is a major public health concern globally and domestically. Dyspnea experienced by hospitalized pneumonia patients often induces anxiety and psychological distress. Wintergreen essential oil, primarily composed of methyl salicylate, is commonly used for comfort care and respiratory relief. This study aims to evaluate the effects of wintergreen essential oil inhalation on dyspnea, physiological parameters, laboratory data, pulmonary function, and subjective comfort in hospitalized pneumonia patients.
The 7 groups in the trial
- Waiting Control GroupNo study treatment, for comparison
Participants receive standard routine medical and nursing care for pneumonia without receiving any essential oil or placebo oil inhalation intervention during the study period.
- Placebo Control GroupPlacebo, for comparison
Participants receive routine care plus sunflower oil inhalation. A dose of 0.5 mL (10 drops) of pure sunflower oil is applied to a 2-inch gauze and held 5 cm from the participant's nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.
Treatment: Sunflower oil inhalation
- Positive Control Group (1% Linalool)Existing treatment, for comparison
Participants receive routine care plus 1% linalool inhalation (diluted in sunflower oil). A dose of 0.5 mL (10 drops) is applied to a 2-inch gauze held 5 cm from the nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.
Treatment: 1% Linalool inhalation
- 0.5% Wintergreen Oil GroupTreatment being tested
Participants receive routine care plus 0.5% wintergreen essential oil inhalation (diluted in sunflower oil). A dose of 0.5 mL (10 drops) is applied to a 2-inch gauze held 5 cm from the nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.
Treatment: Wintergreen essential oil inhalation
- 1% Wintergreen Oil GroupTreatment being tested
Participants receive routine care plus 1% wintergreen essential oil inhalation (diluted in sunflower oil). A dose of 0.5 mL (10 drops) is applied to a 2-inch gauze held 5 cm from the nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.
Treatment: Wintergreen essential oil inhalation
- 2% Wintergreen Oil GroupTreatment being tested
Participants receive routine care plus 2% wintergreen essential oil inhalation (diluted in sunflower oil). A dose of 0.5 mL (10 drops) is applied to a 2-inch gauze held 5 cm from the nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.
Treatment: Wintergreen essential oil inhalation
- 3% Wintergreen Oil GroupTreatment being tested
Participants receive routine care plus 3% wintergreen essential oil inhalation (diluted in sunflower oil). A dose of 0.5 mL (10 drops) is applied to a 2-inch gauze held 5 cm from the nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.
Treatment: Wintergreen essential oil inhalation
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07894835, who can take part
- Record updated
- 26 October 2026